APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Treating Hyperuricemia

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Treating Hyperuricemia Market Outlook and Growth Opportunities 2026

27 December 2025190 pages

Choose your research edition.

Industry ResearchDrugs for Treating Hyperuricemia Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Treating Hyperuricemia Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Drugs for Treating Hyperuricemia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Treating Hyperuricemia Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Treating Hyperuricemia Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Drugs for Treating Hyperuricemia market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for Treating Hyperuricemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Treating Hyperuricemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Treating Hyperuricemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for Treating Hyperuricemia market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for Treating Hyperuricemia market include Teva, 三和化学研究所, Sanofi, Towa Pharmaceutical, Toa Eiyo, Takeda Pharmaceuticals, Mylan Pharmaceuticals, Mochida Pharmaceutical and Lannett Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for Treating Hyperuricemia market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Treating Hyperuricemia and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Treating Hyperuricemia sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Treating Hyperuricemia market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Treating Hyperuricemia Segment by Company

Teva

三和化学研究所

Sanofi

Towa Pharmaceutical

Toa Eiyo

Takeda Pharmaceuticals

Mylan Pharmaceuticals

Mochida Pharmaceutical

Lannett Company

Horizo​​n Therapeutics

GSK

Fuji Yakuhin

AstraZeneca

Drugs for Treating Hyperuricemia Segment by Type

Urate-stimulating Excretion Agents

Uric Acid Production Inhibitors

Other

Drugs for Treating Hyperuricemia Segment by Application

Retail Pharmacies

Hospitals and Clinics

Other

Drugs for Treating Hyperuricemia Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Treating Hyperuricemia status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Drugs for Treating Hyperuricemia market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Treating Hyperuricemia significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Treating Hyperuricemia competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Treating Hyperuricemia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Treating Hyperuricemia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Treating Hyperuricemia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Treating Hyperuricemia market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Treating Hyperuricemia industry.

Chapter 3: Detailed analysis of Drugs for Treating Hyperuricemia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Drugs for Treating Hyperuricemia in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Drugs for Treating Hyperuricemia in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Treating Hyperuricemia Industry Trends Table 2. Drugs for Treating Hyperuricemia Industry Drivers Table 3. Drugs for Treating Hyperuricemia Industry Opportunities and Challenges Table 4. Drugs for Treating Hyperuricemia Industry Restraints Table 5. Global Drugs for Treating Hyperuricemia Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Treating Hyperuricemia Revenue Share by Company (2021-2026) Table 7. Global Drugs for Treating Hyperuricemia Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Drugs for Treating Hyperuricemia Sales Volume Share by Company (2021-2026) Table 9. Global Drugs for Treating Hyperuricemia Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Drugs for Treating Hyperuricemia Company Ranking, (2024-2026) & (USD Million) Table 11. Global Drugs for Treating Hyperuricemia Key Company Manufacturing Base & Headquarters Table 12. Global Drugs for Treating Hyperuricemia Company, Product Type & Application Table 13. Global Drugs for Treating Hyperuricemia Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Treating Hyperuricemia by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Urate-stimulating Excretion Agents Table 18. Significant Companies of Uric Acid Production Inhibitors Table 19. Significant Companies of Other Table 20. Global Drugs for Treating Hyperuricemia Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Drugs for Treating Hyperuricemia Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Drugs for Treating Hyperuricemia Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Drugs for Treating Hyperuricemia Sales Volume Share by Type (2021-2026) Table 24. Global Drugs for Treating Hyperuricemia Sales Volume Share by Type (2027-2032) Table 25. Global Drugs for Treating Hyperuricemia Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs for Treating Hyperuricemia Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Drugs for Treating Hyperuricemia Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Drugs for Treating Hyperuricemia Sales Value Share by Type (2021-2026) Table 29. Global Drugs for Treating Hyperuricemia Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Retail Pharmacies Table 31. Significant Companies of Hospitals and Clinics Table 32. Significant Companies of Other Table 33. Global Drugs for Treating Hyperuricemia Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Drugs for Treating Hyperuricemia Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Drugs for Treating Hyperuricemia Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Drugs for Treating Hyperuricemia Sales Volume Share by Application (2021-2026) Table 37. Global Drugs for Treating Hyperuricemia Sales Volume Share by Application (2027-2032) Table 38. Global Drugs for Treating Hyperuricemia Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Drugs for Treating Hyperuricemia Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Drugs for Treating Hyperuricemia Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Drugs for Treating Hyperuricemia Sales Value Share by Application (2021-2026) Table 42. Global Drugs for Treating Hyperuricemia Sales Value Share by Application (2027-2032) Table 43. Global Drugs for Treating Hyperuricemia Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Drugs for Treating Hyperuricemia Sales by Region (2021-2026) & (K Units) Table 45. Global Drugs for Treating Hyperuricemia Sales Market Share by Region (2021-2026) Table 46. Global Drugs for Treating Hyperuricemia Sales by Region (2027-2032) & (K Units) Table 47. Global Drugs for Treating Hyperuricemia Sales Market Share by Region (2027-2032) Table 48. Global Drugs for Treating Hyperuricemia Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Drugs for Treating Hyperuricemia Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Drugs for Treating Hyperuricemia Sales Value Share by Region (2021-2026) Table 51. Global Drugs for Treating Hyperuricemia Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Drugs for Treating Hyperuricemia Sales Value Share by Region (2027-2032) Table 53. Global Drugs for Treating Hyperuricemia Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Drugs for Treating Hyperuricemia Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Drugs for Treating Hyperuricemia Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Drugs for Treating Hyperuricemia Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Drugs for Treating Hyperuricemia Sales by Country (2021-2026) & (K Units) Table 58. Global Drugs for Treating Hyperuricemia Sales Market Share by Country (2021-2026) Table 59. Global Drugs for Treating Hyperuricemia Sales by Country (2027-2032) & (K Units) Table 60. Global Drugs for Treating Hyperuricemia Sales Market Share by Country (2027-2032) Table 61. Global Drugs for Treating Hyperuricemia Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Drugs for Treating Hyperuricemia Sales Value Market Share by Country (2021-2026) Table 63. Global Drugs for Treating Hyperuricemia Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Drugs for Treating Hyperuricemia Sales Value Market Share by Country (2027-2032) Table 65. Teva Company Information Table 66. Teva Business Overview Table 67. Teva Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Teva Drugs for Treating Hyperuricemia Product Portfolio Table 69. Teva Recent Development Table 70. 三和化学研究所 Company Information Table 71. 三和化学研究所 Business Overview Table 72. 三和化学研究所 Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. 三和化学研究所 Drugs for Treating Hyperuricemia Product Portfolio Table 74. 三和化学研究所 Recent Development Table 75. Sanofi Company Information Table 76. Sanofi Business Overview Table 77. Sanofi Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Sanofi Drugs for Treating Hyperuricemia Product Portfolio Table 79. Sanofi Recent Development Table 80. Towa Pharmaceutical Company Information Table 81. Towa Pharmaceutical Business Overview Table 82. Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Towa Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio Table 84. Towa Pharmaceutical Recent Development Table 85. Toa Eiyo Company Information Table 86. Toa Eiyo Business Overview Table 87. Toa Eiyo Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Toa Eiyo Drugs for Treating Hyperuricemia Product Portfolio Table 89. Toa Eiyo Recent Development Table 90. Takeda Pharmaceuticals Company Information Table 91. Takeda Pharmaceuticals Business Overview Table 92. Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio Table 94. Takeda Pharmaceuticals Recent Development Table 95. Mylan Pharmaceuticals Company Information Table 96. Mylan Pharmaceuticals Business Overview Table 97. Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio Table 99. Mylan Pharmaceuticals Recent Development Table 100. Mochida Pharmaceutical Company Information Table 101. Mochida Pharmaceutical Business Overview Table 102. Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio Table 104. Mochida Pharmaceutical Recent Development Table 105. Lannett Company Company Information Table 106. Lannett Company Business Overview Table 107. Lannett Company Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Lannett Company Drugs for Treating Hyperuricemia Product Portfolio Table 109. Lannett Company Recent Development Table 110. Horizo​​n Therapeutics Company Information Table 111. Horizo​​n Therapeutics Business Overview Table 112. Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Product Portfolio Table 114. Horizo​​n Therapeutics Recent Development Table 115. GSK Company Information Table 116. GSK Business Overview Table 117. GSK Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. GSK Drugs for Treating Hyperuricemia Product Portfolio Table 119. GSK Recent Development Table 120. Fuji Yakuhin Company Information Table 121. Fuji Yakuhin Business Overview Table 122. Fuji Yakuhin Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Fuji Yakuhin Drugs for Treating Hyperuricemia Product Portfolio Table 124. Fuji Yakuhin Recent Development Table 125. AstraZeneca Company Information Table 126. AstraZeneca Business Overview Table 127. AstraZeneca Drugs for Treating Hyperuricemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. AstraZeneca Drugs for Treating Hyperuricemia Product Portfolio Table 129. AstraZeneca Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Drugs for Treating Hyperuricemia Distributors List Table 133. Drugs for Treating Hyperuricemia Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Drugs for Treating Hyperuricemia Product Image Figure 2. Global Drugs for Treating Hyperuricemia Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Treating Hyperuricemia Sales Value (2021-2032) & (US$ Million) Figure 4. Global Drugs for Treating Hyperuricemia Sales (2021-2032) & (K Units) Figure 5. Global Drugs for Treating Hyperuricemia Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Drugs for Treating Hyperuricemia Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Urate-stimulating Excretion Agents Image Figure 10. Uric Acid Production Inhibitors Image Figure 11. Other Image Figure 12. Global Drugs for Treating Hyperuricemia Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Drugs for Treating Hyperuricemia Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Drugs for Treating Hyperuricemia Sales Volume Share by Type (2021-2032) Figure 15. Global Drugs for Treating Hyperuricemia Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Drugs for Treating Hyperuricemia Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Drugs for Treating Hyperuricemia Sales Value Share by Type (2021-2032) Figure 18. Retail Pharmacies Image Figure 19. Hospitals and Clinics Image Figure 20. Other Image Figure 21. Global Drugs for Treating Hyperuricemia Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Drugs for Treating Hyperuricemia Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Drugs for Treating Hyperuricemia Sales Volume Share by Application (2021-2032) Figure 24. Global Drugs for Treating Hyperuricemia Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Drugs for Treating Hyperuricemia Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Drugs for Treating Hyperuricemia Sales Value Share by Application (2021-2032) Figure 27. Global Drugs for Treating Hyperuricemia Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Drugs for Treating Hyperuricemia Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Drugs for Treating Hyperuricemia Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Drugs for Treating Hyperuricemia Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Drugs for Treating Hyperuricemia Sales Value (2021-2032) & (US$ Million) Figure 32. North America Drugs for Treating Hyperuricemia Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Drugs for Treating Hyperuricemia Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Drugs for Treating Hyperuricemia Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Drugs for Treating Hyperuricemia Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Drugs for Treating Hyperuricemia Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Drugs for Treating Hyperuricemia Sales Value (2021-2032) & (US$ Million) Figure 38. South America Drugs for Treating Hyperuricemia Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Drugs for Treating Hyperuricemia Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Drugs for Treating Hyperuricemia Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Drugs for Treating Hyperuricemia Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Drugs for Treating Hyperuricemia Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Urate-stimulating Excretion Agents
  • Uric Acid Production Inhibitors
  • Other
Applications
  • Retail Pharmacies
  • Hospitals and Clinics
  • Other
Companies covered
  • Teva
  • 三和化学研究所
  • Sanofi
  • Towa Pharmaceutical
  • Toa Eiyo
  • Takeda Pharmaceuticals
  • Mylan Pharmaceuticals
  • Mochida Pharmaceutical
  • Lannett Company
  • Horizo​​n Therapeutics
  • GSK
  • Fuji Yakuhin
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Treating Hyperuricemia Sales Value (2021-2032)
  4. 1.2.2 Global Drugs for Treating Hyperuricemia Sales Volume (2021-2032)
  5. 1.2.3 Global Drugs for Treating Hyperuricemia Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Drugs for Treating Hyperuricemia Market Dynamics
  1. 2.1 Drugs for Treating Hyperuricemia Industry Trends
  2. 2.2 Drugs for Treating Hyperuricemia Industry Drivers
  3. 2.3 Drugs for Treating Hyperuricemia Industry Opportunities and Challenges
  4. 2.4 Drugs for Treating Hyperuricemia Industry Restraints
3 Drugs for Treating Hyperuricemia Market by Company
  1. 3.1 Global Drugs for Treating Hyperuricemia Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Treating Hyperuricemia Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Treating Hyperuricemia Sales Volume by Company (2021-2026)
  4. 3.4 Global Drugs for Treating Hyperuricemia Average Price by Company (2021-2026)
  5. 3.5 Global Drugs for Treating Hyperuricemia Company Ranking (2024-2026)
  6. 3.6 Global Drugs for Treating Hyperuricemia Company Manufacturing Base and Headquarters
  7. 3.7 Global Drugs for Treating Hyperuricemia Company Product Type and Application
  8. 3.8 Global Drugs for Treating Hyperuricemia Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Drugs for Treating Hyperuricemia Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Drugs for Treating Hyperuricemia Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Drugs for Treating Hyperuricemia Market by Type
  1. 4.1 Drugs for Treating Hyperuricemia Type Introduction
  2. 4.1.1 Urate-stimulating Excretion Agents
  3. 4.1.2 Uric Acid Production Inhibitors
  4. 4.1.3 Other
  5. 4.2 Global Drugs for Treating Hyperuricemia Sales Volume by Type
  6. 4.2.1 Global Drugs for Treating Hyperuricemia Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Treating Hyperuricemia Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Drugs for Treating Hyperuricemia Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Drugs for Treating Hyperuricemia Sales Value by Type
  10. 4.3.1 Global Drugs for Treating Hyperuricemia Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Drugs for Treating Hyperuricemia Sales Value by Type (2021-2032)
  12. 4.3.3 Global Drugs for Treating Hyperuricemia Sales Value Share by Type (2021-2032)
5 Drugs for Treating Hyperuricemia Market by Application
  1. 5.1 Drugs for Treating Hyperuricemia Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospitals and Clinics
  4. 5.1.3 Other
  5. 5.2 Global Drugs for Treating Hyperuricemia Sales Volume by Application
  6. 5.2.1 Global Drugs for Treating Hyperuricemia Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Treating Hyperuricemia Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Drugs for Treating Hyperuricemia Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Drugs for Treating Hyperuricemia Sales Value by Application
  10. 5.3.1 Global Drugs for Treating Hyperuricemia Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Drugs for Treating Hyperuricemia Sales Value by Application (2021-2032)
  12. 5.3.3 Global Drugs for Treating Hyperuricemia Sales Value Share by Application (2021-2032)
6 Drugs for Treating Hyperuricemia Regional Sales and Value Analysis
  1. 6.1 Global Drugs for Treating Hyperuricemia Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Treating Hyperuricemia Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Treating Hyperuricemia Sales by Region: 2021-2026
  4. 6.2.2 Global Drugs for Treating Hyperuricemia Sales by Region (2027-2032)
  5. 6.3 Global Drugs for Treating Hyperuricemia Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Drugs for Treating Hyperuricemia Sales Value by Region (2021-2032)
  7. 6.4.1 Global Drugs for Treating Hyperuricemia Sales Value by Region: 2021-2026
  8. 6.4.2 Global Drugs for Treating Hyperuricemia Sales Value by Region (2027-2032)
  9. 6.5 Global Drugs for Treating Hyperuricemia Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Drugs for Treating Hyperuricemia Sales Value (2021-2032)
  12. 6.6.2 North America Drugs for Treating Hyperuricemia Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Drugs for Treating Hyperuricemia Sales Value (2021-2032)
  15. 6.7.2 Europe Drugs for Treating Hyperuricemia Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Drugs for Treating Hyperuricemia Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Drugs for Treating Hyperuricemia Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Drugs for Treating Hyperuricemia Sales Value (2021-2032)
  21. 6.9.2 South America Drugs for Treating Hyperuricemia Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Drugs for Treating Hyperuricemia Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Drugs for Treating Hyperuricemia Sales Value Share by Country, 2025 VS 2032
7 Drugs for Treating Hyperuricemia Country-level Sales and Value Analysis
  1. 7.1 Global Drugs for Treating Hyperuricemia Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Treating Hyperuricemia Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Drugs for Treating Hyperuricemia Sales by Country (2021-2032)
  4. 7.3.1 Global Drugs for Treating Hyperuricemia Sales by Country (2021-2026)
  5. 7.3.2 Global Drugs for Treating Hyperuricemia Sales by Country (2027-2032)
  6. 7.4 Global Drugs for Treating Hyperuricemia Sales Value by Country (2021-2032)
  7. 7.4.1 Global Drugs for Treating Hyperuricemia Sales Value by Country (2021-2026)
  8. 7.4.2 Global Drugs for Treating Hyperuricemia Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Drugs for Treating Hyperuricemia Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Drugs for Treating Hyperuricemia Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Drugs for Treating Hyperuricemia Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Drugs for Treating Hyperuricemia Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 三和化学研究所
  8. 8.2.1 三和化学研究所 Company Information
  9. 8.2.2 三和化学研究所 Business Overview
  10. 8.2.3 三和化学研究所 Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 三和化学研究所 Drugs for Treating Hyperuricemia Product Portfolio
  12. 8.2.5 三和化学研究所 Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Drugs for Treating Hyperuricemia Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Towa Pharmaceutical
  20. 8.4.1 Towa Pharmaceutical Company Information
  21. 8.4.2 Towa Pharmaceutical Business Overview
  22. 8.4.3 Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Towa Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio
  24. 8.4.5 Towa Pharmaceutical Recent Developments
  25. 8.5 Toa Eiyo
  26. 8.5.1 Toa Eiyo Company Information
  27. 8.5.2 Toa Eiyo Business Overview
  28. 8.5.3 Toa Eiyo Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Toa Eiyo Drugs for Treating Hyperuricemia Product Portfolio
  30. 8.5.5 Toa Eiyo Recent Developments
  31. 8.6 Takeda Pharmaceuticals
  32. 8.6.1 Takeda Pharmaceuticals Company Information
  33. 8.6.2 Takeda Pharmaceuticals Business Overview
  34. 8.6.3 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio
  36. 8.6.5 Takeda Pharmaceuticals Recent Developments
  37. 8.7 Mylan Pharmaceuticals
  38. 8.7.1 Mylan Pharmaceuticals Company Information
  39. 8.7.2 Mylan Pharmaceuticals Business Overview
  40. 8.7.3 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio
  42. 8.7.5 Mylan Pharmaceuticals Recent Developments
  43. 8.8 Mochida Pharmaceutical
  44. 8.8.1 Mochida Pharmaceutical Company Information
  45. 8.8.2 Mochida Pharmaceutical Business Overview
  46. 8.8.3 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio
  48. 8.8.5 Mochida Pharmaceutical Recent Developments
  49. 8.9 Lannett Company
  50. 8.9.1 Lannett Company Company Information
  51. 8.9.2 Lannett Company Business Overview
  52. 8.9.3 Lannett Company Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Lannett Company Drugs for Treating Hyperuricemia Product Portfolio
  54. 8.9.5 Lannett Company Recent Developments
  55. 8.10 Horizo​​n Therapeutics
  56. 8.10.1 Horizo​​n Therapeutics Company Information
  57. 8.10.2 Horizo​​n Therapeutics Business Overview
  58. 8.10.3 Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Product Portfolio
  60. 8.10.5 Horizo​​n Therapeutics Recent Developments
  61. 8.11 GSK
  62. 8.11.1 GSK Company Information
  63. 8.11.2 GSK Business Overview
  64. 8.11.3 GSK Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 GSK Drugs for Treating Hyperuricemia Product Portfolio
  66. 8.11.5 GSK Recent Developments
  67. 8.12 Fuji Yakuhin
  68. 8.12.1 Fuji Yakuhin Company Information
  69. 8.12.2 Fuji Yakuhin Business Overview
  70. 8.12.3 Fuji Yakuhin Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Fuji Yakuhin Drugs for Treating Hyperuricemia Product Portfolio
  72. 8.12.5 Fuji Yakuhin Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Drugs for Treating Hyperuricemia Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Drugs for Treating Hyperuricemia Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Treating Hyperuricemia Value Chain Analysis
  2. 9.1.1 Drugs for Treating Hyperuricemia Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Treating Hyperuricemia Sales Mode & Process
  6. 9.2 Drugs for Treating Hyperuricemia Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Treating Hyperuricemia Distributors
  9. 9.2.3 Drugs for Treating Hyperuricemia Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst